Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report

• Published in: International journal of colorectal disease 2016-07, Vol.31 (7), p.1349-1357
• Main Authors: Huang, Meijin, Lin, Jinxin, Yu, Xihu, Chen, Shen, Kang, Liang, Deng, Yanhong, Zheng, Jian, Luo, Yanxin, Wang, Lei, Lan, Ping, Wang, Jianping
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Cancer; Care and treatment; Chemoradiotherapy; Colorectal cancer; Demography; Erectile Dysfunction - physiopathology; Gastroenterology; Hepatology; Humans; Impotence; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy; Original Article; Proctology; Rectal Neoplasms - physiopathology; Rectal Neoplasms - therapy; Surgery; Urination
• ISSN: 0179-1958; 1432-1262
• DOI: 10.1007/s00384-016-2605-7

Objective The aim was to evaluate erectile and urinary function of male patients with rectal cancer treated by neoadjuvant (NA) chemoradiotherapy (CRT) or NA chemotherapy only. Methods In this prospective randomized trial (ClinicalTrials.gov NCT01211210; “FOWARC”), we included 102 men who received NA therapy for stage II–III rectal cancer between January 2011 and June 2013. Before surgery, patients received either NA mFOLFOX6 chemotherapy with radiation (RCS group, n  = 54) or NA mFOLFOX6 chemotherapy alone (CS group, n  = 48). Erectile and urinary dysfunctions were assessed with the five-item International Index of Erectile Function (IIEF-5) scale and the International Prostatic Symptom Score (IPSS), respectively. Questionnaires were completed at baseline and at 3, 6, and 12 months (t0–t3, respectively) after surgery. Results At t3, mean IIEF-5 score was significant higher in the CS group (15.3 ± 5.5) than in the RCS group (12.6 ± 5.7; P